文献速递免疫规划

九价与二价HPV疫苗混合接种方案的免疫原性与安全性随机试验

Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
PubMed 文献 · Vaccine · 2018-10-09

371名9-10岁儿童随机接受两剂九价HPV疫苗或九价与二价混合方案(间隔6个月)。混合方案对HPV16/18抗体GMT更高,两剂九价对其他7型GMT更高;首剂二价局部或全身不良事件报告率更高,第二剂后两组无差异。所有方案均具免疫原性且安全性可接受。

要点

  • 混合方案与两剂九价方案在第二剂后均使全部受试者对9种HPV型别血清阳性。
  • 混合方案抗HPV16和18 GMT高于两剂九价,其他7型GMT低于两剂九价。
  • 首剂接种二价者局部或全身不良事件报告率高于首剂接种九价者。

核心结论

  • 本研究的混合HPV疫苗接种方案具有免疫原性且安全性可接受;尽管血清保护阈值未知,第二剂后所有组对9种型别100%血清阳性和GMT升高提示无论何种方案均可能获得保护。

研究设计与样本

  • 随机临床试验,371名9-10岁女孩和男孩按1:1随机分组,分别接种两剂九价HPV疫苗或二价+九价/九价+二价的混合方案,间隔6个月。

主要发现

  • 首剂九价后99.4-100%受试者对疫苗包含的9种HPV型别血清阳性,GMTs为5.0-73.6 IU(AU)/ml(依型别而异)。
  • 首剂二价后所有受试者对HPV16和18血清阳性(GMTs分别为16.7和11.7 IU/ml),50.0-76.7%对二价未包含的7种型别血清阳性(GMTs为0.3-17.5 AU/ml)。
  • 第二剂后所有受试者 regardless of 研究组均对九价包含的9种HPV型别血清阳性。
  • 混合方案组抗HPV16和18 GMTs高于两剂九价组,而其他7种型别GMTs在两剂九价组更高。
  • 首剂接种二价者报告局部或全身不良事件的比例高于首剂接种九价者;第二剂后两种疫苗报告的不良事件无差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data is available on the use of different HPV vaccines in the same subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent (9vHPV) and one dose of bivalent vaccine (2vHPV) administered in different order versus two doses of 9vHPV vaccine. METHODS: 371 girls and boys aged 9-10 years were randomized (1:1) to receive (I) two doses of 9vHPV or (II) a mixed schedule of 2vHPV + 9vHPV or 9vHPV + 2vHPV with a 6 month interval. Antibodies to HPV were tested by ELISA in blood samples collected one or six months post-first dose and one month post-second dose. RESULTS: Post-first dose of 9vHPV 99.4-100% of subjects were seropositive to 9 HPV types included in the vaccine. GMTs varied from 5.0 to 73.6 IU(AU)/ml depending on HPV type. Post-first dose of 2vHPV all subjects were seropositive to HPV16 and 18 (GMTs 16.7 and 11.7 IU/ml, respectively) and 50.0-76.7% were seropositive to 7 types not included in 2vHPV (GMTs varied from 0.3 to 17.5 AU/ml depending on type). Post-second dose all subjects, regardless of the study group, were seropositive to 9 HPV types included in 9vHPV. Anti-HPV16 and 18 GMTs were higher in subjects with the mixed schedule and for the other 7 HPV types higher in subjects who received two doses of 9vHPV vaccine. A higher proportion of subjects who received 2vHPV reported local or systemic adverse events than those who received 9vHPV as the first dose. Post-second dose there were no differences in reported adverse events between the two vaccines. CONCLUSIONS: The results show the mixed HPV vaccination schedules used in this study are immunogenic and have an acceptable safety profile. Although the seroprotective threshold of antibodies remains unknown the 100% seropositivity to all 9 HPV types included in 9vHPV and the increase of GMTs observed in all study groups post-second dose administration are reassuring and suggest protection might be achieved regardless of the schedule used. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov NCT02567955.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gilca V, Sauvageau C, Panicker G, et al. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018. PMID: 30314913. doi:10.1016/j.vaccine.2018.09.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。